- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03970304
CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults
This is an open-label, non-randomized study. The purpose of this study is to better understand how vaccines against typhoid fever affect the normal immune system and bacteria in the intestine. Patients having standard-of-care colonoscopies will be divided into 3 groups:
Group 1: Vivotif typhoid vaccination then colonoscopy; Group 2: Colonoscopy, then Vivotif typhoid vaccination, then follow-up colonoscopy; Group 3: Colonoscopy without vaccination.
The Vivotif typhoid vaccine used in this study is licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will be asked to donate tissue, blood, saliva and stool samples for studying how the body responds to the typhoid vaccine.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Universtiy of Maryland, Baltimore, Center for Vaccine Development and Global Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years and older
- Undergoing colonoscopy for screening or surveillance for colorectal cancer at the University of Maryland
- Provide written informed consent prior to initiation of any study procedures
- Healthy, as defined by considered fit to undergo outpatient elective colonoscopy by the referring health care provider
Exclusion Criteria:
- Pregnancy or nursing mother
- Known coagulopathy or bleeding disorder preventing mucosal biopsy
- History of Crohn's disease or ulcerative colitis
- Surgical removal of the ileocecal valve or any part of the small or large intestine
- Allergic reaction to oral typhoid vaccine in the past
Immunosuppression from illness or treatment, including
- immune-deficiency disorders such as Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)
- leukemia, lymphoma, or cancers
- immune suppressive medications or treatments, such as corticosteroids or radiation
- Receipt of any other vaccine two weeks prior to receipt of Ty21a
- Positive urine pregnancy test (HCG) prior to colonoscopy or vaccination
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vaccination, Colonoscopy
Individuals receive immunization with Vivotif typhoid vaccine prior to routine colonoscopy examination.
During colonoscopy, small bowel biopsies will be obtained to examine immune responses and microbiota at the mucosal level; brushings will also be obtained.
|
The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
Other Names:
|
Experimental: Colonoscopy, Vacciniation, Colonoscopy
Individuals receive immunization with Vivotif typhoid vaccine after initial colonoscopy exam and specimen collection and prior to a routine follow up colonoscopy examination during which additional specimens will be collected.
|
The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
Other Names:
|
No Intervention: Colonoscopy Without Vaccination
Individuals do not receive immunization but consent to collection of specimens during colonoscopy.
The specimens to be collected in all three groups include stool, saliva, and small bowel biopsies (terminal ileum).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Responders
Time Frame: approximately 5 years
|
Percentage of responders by cytokine production (Interferon-gamma (IFN-gamma) or Tumor Necrosis Factor-alpha (TNF-α)) by mass cytometry or flow cytometry.
Responders will be defined as those volunteers showing increases post-immunization of >0.1% of positive CD8+ cells for IFN-gamma or TNF-α over baseline (pre-immunization) values.)
or Tumor Necrosis Factor-alpha (TNF-α)) by mass cytometry or flow cytometry.
|
approximately 5 years
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Booth JS, Goldberg E, Patil SA, Barnes RS, Greenwald BD, Sztein MB. Age-dependency of terminal ileum tissue resident memory T cell responsiveness profiles to S. Typhi following oral Ty21a immunization in humans. Immun Ageing. 2021 Apr 19;18(1):19. doi: 10.1186/s12979-021-00227-y.
- Booth JS, Goldberg E, Barnes RS, Greenwald BD, Sztein MB. Oral typhoid vaccine Ty21a elicits antigen-specific resident memory CD4+ T cells in the human terminal ileum lamina propria and epithelial compartments. J Transl Med. 2020 Feb 25;18(1):102. doi: 10.1186/s12967-020-02263-6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-00056321
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Typhoid Vaccination
-
University of Maryland, BaltimoreRecruitingTyphoid and/or Cholera VaccinationUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of OxfordCompletedTyphoid Vaccine on Sleep
-
University of PennsylvaniaCompletedVaccine Refusal | Vaccination Hesitancy | Human Papillomavirus VaccinationUnited States
-
University of Roma La SapienzaCompletedVaccination Failure | Vaccination Adverse Events | Specific Antibody ResponseItaly
-
International Centre for Diarrhoeal Disease Research...Recruiting
-
International Vaccine InstituteUniversity of Cambridge; Institute of Tropical Medicine, Belgium; Institut National...RecruitingTyphoid FeverCongo, The Democratic Republic of the
-
International Vaccine InstituteBill and Melinda Gates Foundation; SK Bioscience Co., Ltd.Completed
-
International Vaccine InstituteBill and Melinda Gates Foundation; SK Bioscience Co., Ltd.Completed
-
Helsinki University Central HospitalUnknown
Clinical Trials on Vivotif Typhoid Oral Vaccine
-
University of Maryland, BaltimoreRecruitingTyphoid and/or Cholera VaccinationUnited States
-
Helsinki University Central HospitalUniversity of HelsinkiRecruitingCholera | Typhoid Fever | Vaccine-Preventable DiseasesFinland
-
USDA, Western Human Nutrition Research CenterUniversity of MinnesotaRecruitingInflammation | Typhoid Fever | Vaccine | Intestinal PermeabilityUnited States
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHepatitis A | Influenza | Healthy Adults | TyphoidUnited States
-
USDA, Western Human Nutrition Research CenterActive, not recruitingInflammation | Typhoid Fever | Vaccine | Intestinal PermeabilityUnited States
-
Haukeland University HospitalHelse VestTerminated
-
PT Bio FarmaCompletedSafety Issues | ImmunogenicityIndonesia
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and PreventionNot yet recruitingMeasles | Rubella | Cholera | Typhoid
-
Stanford UniversityBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; World Health Organization and other collaboratorsCompletedTyphoid Fever | Enteric Fever | Salmonella Typhi InfectionIndia